Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Medical Oncology
•
Neuroendocrine Tumors
How would you manage grade 3 neuroendocrine tumor of the gallbladder with positive margins after resection?
Ki-67 65%, positive cystic duct margin. Post-operative DOTANOC and FDG PET negative.
Related Questions
What is your preferred first line therapy in well differentiated GI NET with Ki67 > 55%?
Would you ever use a PET dotatate CT to monitor response of a GEP-NEN that is SSTR positive?
Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?
In G1 metastatic GEP-NET with small lesions visible on PET dotatate, very low burden of disease on CT and no clinical symptoms, are there any data to suggest early lanreotide changes natural history of disease and prolongs OS vs observation until symptoms?
What would be your next step in management for a patient with oligometastatic colon NEC who only achieved stable disease after 4 cycles of carboplatin/etoposide?
What is your preferred approach to low volume unresectable/metastatic favorable risk RCC?
How do you interpret the EBCTCG meta-analysis analyzing the magnitude of benefit of anthracyclines in early stage ER+ breast cancer?
When do you consider performing a diagnostic laparoscopy before neoadjuvant chemotherapy in pancreatic adenocarcinoma patients?
Should patients with co-existing moderate-severe valvular disease (particularly AS and MS) and malignancy requiring radiation therapy undergo more frequent surveillance surface echocardiograms?
Would you offer empiric radiation for a growing mediastinal mass radiographically suspicious for thymoma in a patient who declines surgery?